214 related articles for article (PubMed ID: 18711196)
1. Osteonecrosis of the jaw related to bevacizumab.
Estilo CL; Fornier M; Farooki A; Carlson D; Bohle G; Huryn JM
J Clin Oncol; 2008 Aug; 26(24):4037-8. PubMed ID: 18711196
[No Abstract] [Full Text] [Related]
2. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
[TBL] [Abstract][Full Text] [Related]
3. Osteonecrosis of the jaw and bevacizumab therapy.
Van Poznak C
Breast Cancer Res Treat; 2010 Jul; 122(1):189-91. PubMed ID: 20464477
[No Abstract] [Full Text] [Related]
4. Bevacizumab, sunitinib: osteonecrosis of the jaw.
Prescrire Int; 2011 Jun; 20(117):155. PubMed ID: 21682016
[No Abstract] [Full Text] [Related]
5. A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit.
Dişel U; Beşen AA; Özyılkan Ö; Er E; Canpolat T
Oral Oncol; 2012 Feb; 48(2):e2-3. PubMed ID: 21865077
[No Abstract] [Full Text] [Related]
6. Osteonecrosis after administration of intravitreous bevacizumab.
Hopp RN; Pucci J; Santos-Silva AR; Jorge J
J Oral Maxillofac Surg; 2012 Mar; 70(3):632-5. PubMed ID: 21757280
[No Abstract] [Full Text] [Related]
7. Bevacizumab (Avastin): An anti-angiogenic drug associated with osteonecrosis of the jaw.
Wynn RL
Gen Dent; 2011; 59(6):410-3. PubMed ID: 22313910
[No Abstract] [Full Text] [Related]
8. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone.
Christodoulou C; Pervena A; Klouvas G; Galani E; Falagas ME; Tsakalos G; Visvikis A; Nikolakopoulou A; Acholos V; Karapanagiotidis G; Batziou E; Skarlos DV
Oncology; 2009; 76(3):209-11. PubMed ID: 19212145
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab-associated osteonecrosis of the jaw.
Greuter S; Schmid F; Ruhstaller T; Thuerlimann B
Ann Oncol; 2008 Dec; 19(12):2091-2. PubMed ID: 18977851
[No Abstract] [Full Text] [Related]
10. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
Ngamphaiboon N; Frustino JL; Kossoff EB; Sullivan MA; O'Connor TL
Clin Breast Cancer; 2011 Aug; 11(4):252-7. PubMed ID: 21729657
[TBL] [Abstract][Full Text] [Related]
11. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
Sivolella S; Lumachi F; Stellini E; Favero L
Anticancer Res; 2013 May; 33(5):1793-7. PubMed ID: 23645723
[TBL] [Abstract][Full Text] [Related]
12. Osteonecrosis of jaw with the use of denosumab.
Akhtar NH; Afzal MZ; Ahmed AA
J Cancer Res Ther; 2011; 7(4):499-500. PubMed ID: 22269422
[No Abstract] [Full Text] [Related]
13. A new class of drugs to prevent osteoporosis may be associated with osteonecrosis of the jaw.
Wynn RL
Gen Dent; 2011; 59(1):10-2. PubMed ID: 21613033
[No Abstract] [Full Text] [Related]
14. [A case of osteonecrosis of the jaw during treatment by bevacizumab for sigmoid colon cancer].
Sato M; Ono F; Yamamura A; Onochi S
Nihon Shokakibyo Gakkai Zasshi; 2013 Apr; 110(4):655-9. PubMed ID: 23558129
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab-related osteneocrosis of the jaw.
Serra E; Paolantonio M; Spoto G; Mastrangelo F; Tetè S; Dolci M
Int J Immunopathol Pharmacol; 2009; 22(4):1121-3. PubMed ID: 20074477
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab (Avastin) for metastic breast cancer.
Med Lett Drugs Ther; 2008 Jun; 50(1287):42-3. PubMed ID: 18509265
[No Abstract] [Full Text] [Related]
17. Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer.
Karachaliou N; Saloustros E; Vamvakas L; Mavroudis D; Georgoulias V
Ann Oncol; 2010 Aug; 21(8):1729-1730. PubMed ID: 20601370
[No Abstract] [Full Text] [Related]
18. Osteonecrosis of the jaws and bevacizumab therapy: a case report.
Brunamonti Binello P; Bandelloni R; Labanca M; Buffoli B; Rezzani R; Rodella LF
Int J Immunopathol Pharmacol; 2012; 25(3):789-91. PubMed ID: 23058032
[TBL] [Abstract][Full Text] [Related]
19. Osteonecrosis of the mandible associated with bevacizumab therapy.
Santos-Silva AR; Belizário Rosa GA; Castro Júnior Gd; Dias RB; Prado Ribeiro AC; Brandão TB
Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Jun; 115(6):e32-6. PubMed ID: 23567260
[TBL] [Abstract][Full Text] [Related]
20. New oncology drugs and osteonecrosis of the jaw (ONJ).
Migliorati CA; Covington JS
J Tenn Dent Assoc; 2009; 89(4):36-8; quiz 38-9. PubMed ID: 20102031
[No Abstract] [Full Text] [Related]
[Next] [New Search]
